Potencial terapêutico dos canabinoides em doenças neurodegenerativas: Parkinson, Alzheimer e Esclerose Múltipla
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Jan 25, 2024
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Analisar sobre os efeitos dos canabinoides no tratamento e/ou alívio de sintomas de doenças neurodegenerativas, como: Parkinson, Doença de Alzheimer e Esclerose Múltipla. Métodos: Foi realizada uma revisão integrativa intencionando compilar os principais resultados do uso dos canabinoides na prevenção e controle de doenças neurodegenerativas com foco nas doenças de Parkinson, Alzheimer e Esclerose Múltipla. Foram selecionados artigos científicos disponíveis no portal Periódicos Capes distribuídos nas bases de dados PubMed, Science Direct e Medline. Resultados: Foram encontrados 331 artigos científicos filtrados apenas para testes clínicos, destes após triagem foram lidos integralmente 52 textos e para esta revisão foram selecionados 21 artigos. Os artigos selecionados demonstram resultados positivos na melhora de sintomas e na qualidade de vida geral em todas as patologias. A maioria dos estudos foram realizados em países europeus, demonstrando a necessidade de maiores investimentos em pesquisas clínicas com canabinoides principalmente na América do Sul. Considerações finais: Com a análise dos textos é possível concluir que os canabinoides Tetra-hidrocanabinol (THC) e Canabidiol (CBD) são compostos benéficos em testes clínicos com resultados positivos no controle e prevenção de sintomas das três doenças neurodegenerativas escolhidas para esta revisão.
##plugins.themes.bootstrap3.article.details##
Como Citar
SantosB. W. dos, FernandesI. da C., DiasJ. de F. G., MontrucchioD. P., DalarmiL., MiguelO. G., & MiguelM. D. (2024). Potencial terapêutico dos canabinoides em doenças neurodegenerativas: Parkinson, Alzheimer e Esclerose Múltipla. Revista Eletrônica Acervo Saúde, 24(1), e15296. https://doi.org/10.25248/reas.e15296.2024
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. ALVES B, et al. Esclerose múltipla: revisão dos principais tratamentos da doença. Saúde e Meio Ambiente: Revista Interdisciplinar, 2015; 3(2): 19–34.
2. AMERONGEN G, et al. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients with Progressive Multiple Sclerosis. Clinical therapeutics, 2018; 40(9): 1467–1482.
3. ARAGONA M, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clinical neuropharmacology, 2009; 32(1): 41–47.
4. CONTE A, et al. Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. European Journal of Pain, 2009; 13: 472-477.
5. CARROLL CB, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology, 2004; 63(7): 1245–1250.
6. CHAGAS MH, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. Journal of psychopharmacology, 2014; 28(11): 1088–1098.
7. CORREIA-DA-SILVA G, et al. Canábis e canabinóides para fins medicinais. Revista Portuguesa De Farmacoterapia, 2019; 11(1): 21-31.
8. FARIA SM, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. Journal of psychopharmacology, 2020; 34(2): 189–196.
9. FILHO R, et al. O potencial terapêutico do Canabidiol em doenças neurodegenerativas. Acta Farmacêutica Portuguesa 2021; 10(1): 84-103.
10. FREEMAN RM, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). International urogynecology journal and pelvic floor dysfunction, 2006; 17(6): 636–641.
11. HAUPTS M, et al. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity. European neurology, 2016; 75(5-6): 236–243.
12. HERRMANN N, et al. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. The American journal of geriatric psychiatry, 2019; 27(11): 1161–1173.
13. HONÓRIO KM, et al. Aspectos terapêuticos de compostos da planta Cannabis sativa. Química Nova, 2006; 29(2): 318–325.
14. KILLESTEIN J, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 2002; 58(9): 1404–1407.
15. KANCHI PK e DASMAHAPATRA AK. Destabilization of the Alzheimer’s amyloid-β protofibrils by THC: A molecular dynamics simulation study. Journal of Molecular Graphics and Modelling, 2021; 105: e107889.
16. LANGFORD RM, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of neurology, 2013; 260(4): 984–997.
17. LEEHEY MA, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. Cannabis and cannabinoid research, 2020; 5(4): 326–336.
18. MENDES KDS, et al., Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto - Enfermagem, 2008; 17(4): 758–764.
19. MASSANO J. Doença de Parkinson: actualização clínica. Acta Médica Portuguesa, 2011; 24: 827–34.
20. MECHA M, et al. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiology of Disease, 2013; 59: 141-150.
21. MOREIRA MA, et al. Esclerose múltipla: estudo descritivo de suas formas clínicas em 302 casos. Arquivos de Neuro-psiquiatria, 2010; 58(2B): 460–466.
22. OBERBARNSCHEIDT T e MILLER NS. The Impact of Cannabidiol on Psychiatric and Medical Conditions. J Clinical Medical Research, 2020; 12(7): 393-403.
23. OSORIO JH e TANGARIFE HF. CANNABIS, UNA OPCIÓN TERAPÉUTICA. Biosalud, 2009; 8(1): 166-177.
24. PIOMELLI D, et al. Regulatory Barriers to Research on Cannabis and Cannabinoids: A Proposed Path Forward. Cannabis Cannabinoid Research, 2019; 4(1): 21-32.
25. ROG DJ, et al. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clinical therapeutics, 2007; 29(9): 2068–2079.
26. ROG DJ, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 2005; 65(6): 812–819.
27. RUTHIRAKUHAN MT, et al. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial, Contemporary Clinical Trials Communications, 2019; 15: e100385.
28. RUSSO EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British journal of pharmacology, 2011; 163(7): 1344–1364.
29. SERENIKI A e VITAL MABF. A doença de Alzheimer: aspectos fisiopatológicos e farmacológicos. Revista De Psiquiatria Do Rio Grande Do Sul, 2008; 30(1).
30. SILVA MT, et al. Efficacy of cannabidiol in improving the quality of life with Parkinson’s Patient: integrative review. Research, Society and Development, 2021;10(13): e09101320768.
31. SILVA HKC e LOURENCO RF. Cannabinoid therapy within the Unified Health System, perspectives in relation to pain treatment. Brazilian Journal of Pain, 2023; 6: 44-48.
32. SOUZA MT, et al. Integrative review: what is it? How to do it? Einstein São Paulo, 2010; 8(1):102–6.
33. SMITH MAC. Doença de Alzheimer. Brazilian Journal of Psychiatry,1999; 21: 03–7.
34. TAMBELI CH, et al. Integrative approach to the therapeutic use of cannabis for orofacial pain. Brazilian Journal of Pain, 2023; 6: 49–53.
35. VECCHIO D, et al. Cannabinoids in multiple sclerosis: A neurophysiological analysis. Acta neurologica Scandinavica, 2020; 142(4): 333–338.
36. VOLICER L, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International journal of geriatric psychiatry, 1997; 12(9): 913–919.
37. WADE DT, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis Journal, 2004; 10(4): 434-441.
38. ZAJICEK JP, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. Journal of neurology, neurosurgery, and psychiatry, 2005; 76(12): 1664–1669.
39. ZAJICEK JP, et al. Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. Journal of Neurology, Neurosurgery & Psychiatry 2012; 83: 1125-1132.
40. ZUARDI AW. History of cannabis as a medicine: a review. Brazilian Journal of Psychiatry, 2006; 28(2): 153–157.
2. AMERONGEN G, et al. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients with Progressive Multiple Sclerosis. Clinical therapeutics, 2018; 40(9): 1467–1482.
3. ARAGONA M, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clinical neuropharmacology, 2009; 32(1): 41–47.
4. CONTE A, et al. Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. European Journal of Pain, 2009; 13: 472-477.
5. CARROLL CB, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology, 2004; 63(7): 1245–1250.
6. CHAGAS MH, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. Journal of psychopharmacology, 2014; 28(11): 1088–1098.
7. CORREIA-DA-SILVA G, et al. Canábis e canabinóides para fins medicinais. Revista Portuguesa De Farmacoterapia, 2019; 11(1): 21-31.
8. FARIA SM, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. Journal of psychopharmacology, 2020; 34(2): 189–196.
9. FILHO R, et al. O potencial terapêutico do Canabidiol em doenças neurodegenerativas. Acta Farmacêutica Portuguesa 2021; 10(1): 84-103.
10. FREEMAN RM, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). International urogynecology journal and pelvic floor dysfunction, 2006; 17(6): 636–641.
11. HAUPTS M, et al. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity. European neurology, 2016; 75(5-6): 236–243.
12. HERRMANN N, et al. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. The American journal of geriatric psychiatry, 2019; 27(11): 1161–1173.
13. HONÓRIO KM, et al. Aspectos terapêuticos de compostos da planta Cannabis sativa. Química Nova, 2006; 29(2): 318–325.
14. KILLESTEIN J, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 2002; 58(9): 1404–1407.
15. KANCHI PK e DASMAHAPATRA AK. Destabilization of the Alzheimer’s amyloid-β protofibrils by THC: A molecular dynamics simulation study. Journal of Molecular Graphics and Modelling, 2021; 105: e107889.
16. LANGFORD RM, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of neurology, 2013; 260(4): 984–997.
17. LEEHEY MA, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. Cannabis and cannabinoid research, 2020; 5(4): 326–336.
18. MENDES KDS, et al., Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto - Enfermagem, 2008; 17(4): 758–764.
19. MASSANO J. Doença de Parkinson: actualização clínica. Acta Médica Portuguesa, 2011; 24: 827–34.
20. MECHA M, et al. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiology of Disease, 2013; 59: 141-150.
21. MOREIRA MA, et al. Esclerose múltipla: estudo descritivo de suas formas clínicas em 302 casos. Arquivos de Neuro-psiquiatria, 2010; 58(2B): 460–466.
22. OBERBARNSCHEIDT T e MILLER NS. The Impact of Cannabidiol on Psychiatric and Medical Conditions. J Clinical Medical Research, 2020; 12(7): 393-403.
23. OSORIO JH e TANGARIFE HF. CANNABIS, UNA OPCIÓN TERAPÉUTICA. Biosalud, 2009; 8(1): 166-177.
24. PIOMELLI D, et al. Regulatory Barriers to Research on Cannabis and Cannabinoids: A Proposed Path Forward. Cannabis Cannabinoid Research, 2019; 4(1): 21-32.
25. ROG DJ, et al. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clinical therapeutics, 2007; 29(9): 2068–2079.
26. ROG DJ, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 2005; 65(6): 812–819.
27. RUTHIRAKUHAN MT, et al. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial, Contemporary Clinical Trials Communications, 2019; 15: e100385.
28. RUSSO EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British journal of pharmacology, 2011; 163(7): 1344–1364.
29. SERENIKI A e VITAL MABF. A doença de Alzheimer: aspectos fisiopatológicos e farmacológicos. Revista De Psiquiatria Do Rio Grande Do Sul, 2008; 30(1).
30. SILVA MT, et al. Efficacy of cannabidiol in improving the quality of life with Parkinson’s Patient: integrative review. Research, Society and Development, 2021;10(13): e09101320768.
31. SILVA HKC e LOURENCO RF. Cannabinoid therapy within the Unified Health System, perspectives in relation to pain treatment. Brazilian Journal of Pain, 2023; 6: 44-48.
32. SOUZA MT, et al. Integrative review: what is it? How to do it? Einstein São Paulo, 2010; 8(1):102–6.
33. SMITH MAC. Doença de Alzheimer. Brazilian Journal of Psychiatry,1999; 21: 03–7.
34. TAMBELI CH, et al. Integrative approach to the therapeutic use of cannabis for orofacial pain. Brazilian Journal of Pain, 2023; 6: 49–53.
35. VECCHIO D, et al. Cannabinoids in multiple sclerosis: A neurophysiological analysis. Acta neurologica Scandinavica, 2020; 142(4): 333–338.
36. VOLICER L, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International journal of geriatric psychiatry, 1997; 12(9): 913–919.
37. WADE DT, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis Journal, 2004; 10(4): 434-441.
38. ZAJICEK JP, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. Journal of neurology, neurosurgery, and psychiatry, 2005; 76(12): 1664–1669.
39. ZAJICEK JP, et al. Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. Journal of Neurology, Neurosurgery & Psychiatry 2012; 83: 1125-1132.
40. ZUARDI AW. History of cannabis as a medicine: a review. Brazilian Journal of Psychiatry, 2006; 28(2): 153–157.